0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Diseases & disorders > Immunology

Buy Now

Antiviral Chemotherapy 5 - New Directions for Clinical Application and Research (Paperback, Softcover reprint of the original 1st ed. 1999) Loot Price: R4,244
Discovery Miles 42 440
Antiviral Chemotherapy 5 - New Directions for Clinical Application and Research (Paperback, Softcover reprint of the original...

Antiviral Chemotherapy 5 - New Directions for Clinical Application and Research (Paperback, Softcover reprint of the original 1st ed. 1999)

John Mills, Paul A. Volberding, Lawrence Corey

Series: Advances in Experimental Medicine and Biology, 458

 (sign in to rate)
Loot Price R4,244 Discovery Miles 42 440 | Repayment Terms: R398 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Scientists and clinicians attending the last "New Directions in Antiviral Therapy" conference in late 1994 could hardly have predicted the revolution in the management of patients with HIV infection that has occurred since. Two new classes of antiretrovirals have been licensed, the second-site RT inhibitors and the protease inhibitors; the long in cubation period of active HIV infection, when the infection is clinically latent, is now un derstood to be a period of intense viral replication and turnover of CD4 lymphocytes; measurements of HI V RNA concentration in plasma have been shown to be essential tools for monitoring the course of HIV infection, deciding when to treat, and assessing the re sults of treatment; and finally, combinations of antiretrovirals, particularly combinations including protease inhibitors, have been shown to have dramatically beneficial effects on patients with HIV infection. These advances, coupled with new drugs for the management of herpesvirus infections, have made dramatic differences in the quality and length of life of HIV-infected patients. Additional advances have been made since 1994 in the prevention or management of influenza virus (zanamavir), respiratory syncytial virus (palvizumab), hepatitis B virus (lamivudine and famciclovir), and enterovirus infections (pleconaril). It is difficult to re member that only slightly more than a decade ago there were only a handful of antiviral agents available (none of which were antiretrovirals), and a number of those were either highly toxic, of dubious efficacy, or both."

General

Imprint: Springer-Verlag New York
Country of origin: United States
Series: Advances in Experimental Medicine and Biology, 458
Release date: December 2012
First published: 1999
Editors: John Mills • Paul A. Volberding • Lawrence Corey
Dimensions: 254 x 178 x 14mm (L x W x T)
Format: Paperback
Pages: 271
Edition: Softcover reprint of the original 1st ed. 1999
ISBN-13: 978-1-4613-7150-2
Categories: Books > Medicine > Other branches of medicine > Pathology > Medical microbiology & virology
Books > Medicine > Other branches of medicine > Pharmacology > General
Books > Science & Mathematics > Biology, life sciences > Biochemistry > General
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Infectious & contagious diseases > General
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Immunology > General
LSN: 1-4613-7150-3
Barcode: 9781461371502

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners